- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07939997
ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma
CLEAR-ESO: ctDNA CLEARance to Predict Successful Non-operative Management and Pathologic Complete Response in ESOphageal Squamous Cell Carcinoma
The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment.
Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance.
The main questions this study aims to answer are:
- Can ctDNA clearance after chemoradiotherapy predict 2-year complete response-disease-free survival?
- Can ctDNA clearance improve the prediction of durable complete response compared with standard response assessment methods, including PET/CT and endoscopy?
- Can ctDNA clearance at different timepoints during and after chemoradiotherapy help identify patients at risk of disease recurrence?
The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care.
Study participants will:
- Provide blood samples at baseline, during Week 3 of chemoradiotherapy, and at completion of chemoradiotherapy for ctDNA analysis.
- Participate in one of two observational cohorts. Participants in the Longitudinal ctDNA Cohort will provide additional blood samples at 6 weeks and 3 months after chemoradiotherapy and every 3 months through 24 months. Participants in the Limited-Sampling Research Cohort will provide only three protocol-required blood samples.
- Continue standard-of-care cancer treatment and follow-up according to treating physician discretion.
- Allow researchers to review medical records to assess treatment response, cancer recurrence, salvage therapy, and survival status through 24 months after completion of chemoradiotherapy.
Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort.
This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Chitra Pai Kulyadi
- Numer telefonu: 857-919-8557
- E-mail: chitra.paikulyadi@cuanschutz.edu
Lokalizacje studiów
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Hospital
-
Kontakt:
- Chitra Pai Kulyadi
- Numer telefonu: 857-919-8557
- E-mail: chitra.paikulyadi@cuanschutz.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Adults aged 18 years or older with histologically confirmed, localized cervical or thoracic esophageal squamous cell carcinoma (ESCC), clinical stage cT1-4 or cTX, N0-3, M0, who are planned to receive curative-intent definitive chemoradiotherapy with active surveillance or neoadjuvant chemoradiotherapy followed by planned esophagectomy.
Eligible participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate pretreatment tumor tissue for tumor-informed circulating tumor DNA (ctDNA) assay generation, and the ability to undergo protocol-specified blood collection.
Participants will be enrolled into one of two observational cohorts: the Longitudinal ctDNA Cohort or the Limited-Sampling Research Cohort. Cohort assignment will be based on participant election, treatment location, and operational feasibility. Participants may receive chemoradiotherapy at participating study sites or, for eligible participants in the Limited-Sampling Research Cohort,
Opis
Inclusion Criteria:
- Provision to sign and date the consent form.
- Stated willingness to comply with all study procedures and be available for the duration of the study.
- Age ≥18 years.
- Histologically confirmed cervical or thoracic esophageal squamous cell carcinoma (ESCC). For cervical tumors (defined per NCCN as <5 cm from cricopharyngeus), the primary site must be the cervical esophagus rather than a primary hypopharyngeal malignancy as determined by the treating multidisciplinary team.
- Clinical stage cT1-4 or cTX, N0-3, M0 disease according to AJCC 8th Edition staging, based on available standard-of-care staging studies and treating investigator assessment. EUS is not required when nodal disease or other standard staging information is sufficient to support treatment with chemoradiotherapy
- Planned treatment with curative-intent chemoradiotherapy, including either:
- definitive chemoradiotherapy with surveillance intent, or neoadjuvant chemoradiotherapy with planned esophagectomy. Induction chemotherapy prior to chemoradiation is allowed, as well as the use of immunotherapy during the treatment course per physician discretion as part of curative-intent therapy.
- For thoracic or cervical ESCC, the planned radiation dose and fractionation must be consistent with a definitive chemoradiotherapy regimen according to institutional standards, regardless of whether treatment is delivered with neoadjuvant or definitive intent.
- Availability of pretreatment tumor tissue adequate for tumor-informed ctDNA assay generation.
- Ability to undergo protocol-specified peripheral blood collection for ctDNA analysis according to the assigned cohort, including mobile phlebotomy when applicable.
- ECOG performance status 0-2.
- Adequate baseline clinical evaluation completed per institutional standard, including staging PET/CT and endoscopic assessment.
Exclusion Criteria:
- Evidence of metastatic (M1) disease.
- Histology other than squamous cell carcinoma (including adenocarcinoma, small cell carcinoma, or mixed histology with predominant non-squamous features).
- Prior thoracic radiotherapy overlapping planned treatment fields.
- Inability to obtain adequate tumor tissue for ctDNA assay generation.
- Active second malignancy requiring systemic therapy that could confound ctDNA interpretation, except adequately treated non-melanoma skin cancer or localized malignancies under surveillance.
- Patients unable or unwilling to comply with serial blood collection or clinical follow-up requirements of either study cohort.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
CLEAR-ESO Longitudinal ctDNA Cohort
The Longitudinal ctDNA Cohort additionally obtains ctDNA at 6 weeks post-CRT, 3 months post-CRT, and every 3 months through 24 months, and physician decision-impact surveys assess whether ctDNA findings influence clinical management. |
Peripheral blood samples are collected for tumor-informed circulating tumor DNA (ctDNA) assessment using the Signatera™ Genome Assay. ctDNA testing is performed at protocol-defined time points to evaluate ctDNA clearance and kinetics in participants with localized esophageal squamous cell carcinoma undergoing standard-of-care chemoradiotherapy. Results are returned through routine clinical workflows; no protocol-mandated treatment modifications are required based on ctDNA results. |
|
CLEAR-ESO Limited-Sampling Research Cohort
Participants in the Limited-Sampling Research Cohort undergo tumor-informed ctDNA assessment at baseline, Week 3 of CRT, and completion of CRT. Results are returned through routine clinical workflows. No physician decision-impact surveys are administered, and no protocol-directed ctDNA collections occur after completion of CRT. Clinical outcome data are collected through approximately 24 months following CRT. |
Peripheral blood samples are collected for tumor-informed circulating tumor DNA (ctDNA) assessment using the Signatera™ Genome Assay. ctDNA testing is performed at protocol-defined time points to evaluate ctDNA clearance and kinetics in participants with localized esophageal squamous cell carcinoma undergoing standard-of-care chemoradiotherapy. Results are returned through routine clinical workflows; no protocol-mandated treatment modifications are required based on ctDNA results. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants Achieving 2-Year Complete Response-Disease-Free Survival (CR-DFS)
Ramy czasowe: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
|
The percentage of participants achieving 2-year complete response-disease-free survival (CR-DFS) across both neoadjuvant and definitive chemoradiotherapy (CRT) pathways. CR-DFS is defined as pathologic complete response (ypT0N0) among participants undergoing esophagectomy or sustained clinical complete response among participants managed with definitive CRT and active surveillance, without locoregional recurrence, distant recurrence, death, or requirement for salvage esophagectomy within 24 months of completing CRT. The primary analysis will compare 2-year CR-DFS rates between participants with and without circulating tumor DNA (ctDNA) clearance at completion of CRT, stratified by treatment pathway. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT. A common odds ratio with a 95% confidence interval will be reported. |
From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sensitivity of ctDNA Clearance for Predicting 2-Year CR-DFS
Ramy czasowe: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
Sensitivity of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals. |
Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
|
Specificity of ctDNA Clearance for Predicting 2-Year CR-DFS
Ramy czasowe: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
Specificity of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals. |
Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
|
Positive Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS
Ramy czasowe: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
Positive predictive value of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals |
Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
|
Negative Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS
Ramy czasowe: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
Negative predictive value of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals. |
Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.
|
|
Area Under the Receiver Operating Characteristic Curve (AUC) for ctDNA Clearance, PET/CT, Endoscopy, and Combined Models in Predicting 2-Year CR-DFS
Ramy czasowe: Post-treatment response assessment following completion of CRT; clinical outcome assessment through 24 months post-CRT.
|
Area under the receiver operating characteristic curve (AUC) for ctDNA clearance, PET/CT response, endoscopic response, and combined models for predicting 2-year CR-DFS. Comparative and additive predictive performance will be evaluated to assess the incremental predictive value of ctDNA clearance over standard post-treatment response assessment. |
Post-treatment response assessment following completion of CRT; clinical outcome assessment through 24 months post-CRT.
|
|
Association Between ctDNA Clearance at Week 3 of CRT and 2-Year CR-DFS
Ramy czasowe: Baseline and Week 3 of CRT; outcomes through 24 months post-CRT
|
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol. |
Baseline and Week 3 of CRT; outcomes through 24 months post-CRT
|
|
Association Between ctDNA Clearance at Completion of CRT and 2-Year CR-DFS
Ramy czasowe: Baseline and Week 5 of chemoradiotherapy for thoracic tumors or Week 7 of chemoradiotherapy for cervical tumors; clinical outcomes assessed up to 24 months after completion of chemoradiotherapy
|
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol. |
Baseline and Week 5 of chemoradiotherapy for thoracic tumors or Week 7 of chemoradiotherapy for cervical tumors; clinical outcomes assessed up to 24 months after completion of chemoradiotherapy
|
|
Association Between ctDNA Clearance at 6 Weeks Post-CRT and 2-Year CR-DFS
Ramy czasowe: Baseline through 6 weeks post-CRT; outcomes through 24 months post-CRT
|
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol. |
Baseline through 6 weeks post-CRT; outcomes through 24 months post-CRT
|
|
Association Between ctDNA Clearance at 3 Months Post-CRT and 2-Year CR-DFS
Ramy czasowe: Baseline through 3 months post-CRT; outcomes through 24 months post-CRT
|
Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol. |
Baseline through 3 months post-CRT; outcomes through 24 months post-CRT
|
|
Percentage of Participants With Physician-Reported Changes in Clinical Management Attributable to ctDNA Results
Ramy czasowe: At 3 months and 24 months post-CRT and whenever ctDNA results influence clinical management, through 24 months post-CRT.
|
Frequency and type of physician-reported changes in treatment recommendations or surveillance strategy attributable to ctDNA results, including additional diagnostic testing and/or changes in clinical management. Changes will be assessed using the CLEAR-ESO Physician Decision-Impact Survey in the Longitudinal ctDNA Cohort only. |
At 3 months and 24 months post-CRT and whenever ctDNA results influence clinical management, through 24 months post-CRT.
|
|
Percentage of Participants With ctDNA Clearance According to Baseline Tumor Characteristics
Ramy czasowe: Baseline through completion of chemoradiotherapy (approximately Week 5 for thoracic tumors and up to Week 7 for cervical tumors).
|
The percentage of participants achieving circulating tumor DNA (ctDNA) clearance at completion of chemoradiotherapy (CRT) will be evaluated according to baseline tumor characteristics, including clinical tumor stage, nodal stage, tumor length (cranial-caudal extent), baseline ctDNA burden, and cervical versus thoracic tumor location. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT. |
Baseline through completion of chemoradiotherapy (approximately Week 5 for thoracic tumors and up to Week 7 for cervical tumors).
|
|
Percentage of participants with Locoregional or Distant Recurrence according to ctDNA Status
Ramy czasowe: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
|
The percentage of participants experiencing locoregional or distant recurrence will be evaluated according to circulating tumor DNA (ctDNA) status during surveillance. Recurrence patterns will be characterized using available clinical and radiographic assessments. |
From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.
|
|
Time From ctDNA Positivity to Radiographic or Clinical Recurrence
Ramy czasowe: From completion of CRT through 24 months post-CRT.
|
Interval from ctDNA positivity during surveillance to radiographic or clinical recurrence among participants with documented recurrence. This analysis will characterize the timing of recurrence relative to ctDNA status in the Longitudinal ctDNA Cohort. |
From completion of CRT through 24 months post-CRT.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: David Binder, MD, PhD, University of Colorado, Denver
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Choroby przełyku
- Rak
- Nowotwory, płaskonabłonkowy
- Rak, płaskonabłonkowy
- Rak płaskonabłonkowy przełyku
- Nowotwory przełyku
Inne numery identyfikacyjne badania
- 26-1041.cc
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .